Journal of Dermatology最新文献

{"title":"Characteristics of suitable cases for treatment with nemolizumab based on clinical findings and cutaneous adverse events","authors":"Akiko Sugiyama,&nbsp;Atsuko Yano-Takamori,&nbsp;Kaoru Kojima,&nbsp;Haruko Nishie,&nbsp;Miku Nishimura,&nbsp;Tetsuya Hiramoto,&nbsp;Takeshi Nakahara","doi":"10.1111/1346-8138.17626","DOIUrl":"10.1111/1346-8138.17626","url":null,"abstract":"<p>Nemolizumab is an effective treatment for pruritus in atopic dermatitis, but it has a relatively high incidence of cutaneous adverse events (cAEs). To optimize the use of nemolizumab, we investigated the relationship between baseline severity in specific body areas and the frequency of cAEs. Our findings revealed that cases who discontinued treatment with nemolizumab had more severe erythema and edema/papulation on the trunk than those who continued nemolizumab. We also found that the score of excoriation on the trunk tended to be higher. These results indicate that patients with mild severity of eruptions on the trunk at initiation could be suitable for nemolizumab therapy, with the potential for long-term continuation with the control of cAEs.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 4","pages":"740-743"},"PeriodicalIF":2.9,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143019283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combination treatment of cultured epithelial autograft and meshed full-thickness skin graft for giant congenital melanocytic nevus","authors":"Katsuhiko Nishihara,&nbsp;Kazuyasu Fujii,&nbsp;Megumi Aoki,&nbsp;Yui Hirano,&nbsp;Akiha Inoue,&nbsp;Sotaro Yamamoto,&nbsp;Shigeto Matsushita","doi":"10.1111/1346-8138.17529","DOIUrl":"10.1111/1346-8138.17529","url":null,"abstract":"","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 4","pages":"e268-e269"},"PeriodicalIF":2.9,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143019295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Using patient preference to inform ritlecitinib dose selection for alopecia areata treatment","authors":"Brett Hauber,&nbsp;Chiara Whichello,&nbsp;Jonathan Mauer,&nbsp;Ernest Law,&nbsp;Myrto Trapali,&nbsp;Edward Whalen,&nbsp;Dalia Wajsbrot,&nbsp;Nicolas Krucien,&nbsp;Tommi Tervonen,&nbsp;Samuel H. Zwillich,&nbsp;Robert Wolk","doi":"10.1111/1346-8138.17628","DOIUrl":"10.1111/1346-8138.17628","url":null,"abstract":"<p>Ritlecitinib is an oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma (JAK3/TEC) family kinase inhibitor approved for the treatment of severe alopecia areata (AA). Benefit–risk profiles of two doses of ritlecitinib (50 mg vs 30 mg once daily) were evaluated by integrating patient preferences and clinical efficacy and safety estimates for ritlecitinib. A discrete-choice experiment (DCE) was utilized to elicit preferences for benefit and safety attributes of systemic AA treatments. Benefits included probabilities of ≥80% scalp hair coverage and achieving moderate to normal eyebrows and eyelashes. Potential risks included 3-year probabilities of serious infection, cancer, and blood clots. Preference estimates were used to calculate the maximum acceptable risk (MAR) that patients would accept for expected increases in benefit from choosing a higher ritlecitinib dose over a lower dose. Ritlecitinib benefits were calculated from the ALLEGRO-2b/3 clinical trial. MARs were calculated separately for each risk and jointly for all possible combinations. Adults (<i>n</i> = 201) with physician-confirmed ≥50% scalp hair loss from AA participated. To achieve expected increases in the probabilities of ≥80% scalp hair coverage or moderate to normal eyebrows and eyelashes when choosing 50 mg over 30 mg of ritlecitinib, patients would be willing to accept increases in each 3-year risk up to a mean of 3.88 absolute percentage points (95% confidence interval [CI], 2.86–4.90) for serious infection, 1.63 (95% CI, 1.08–2.18) for cancer, and 5.30 (95% CI, 3.60–7.00) for blood clots. These results, combined with the estimated differences in risks between the two doses, indicate that patients with AA value increases in the probabilities of scalp, eyebrow, and eyelash hair regrowth, with the average patient accepting increases in potential treatment-related risks for the 50-mg dose in exchange for higher efficacy than 30 mg. The DCE approach to measuring risk tolerance, combined with comparisons to expected benefit and risk differences, can be used to optimize AA treatment dose selection.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 3","pages":"510-514"},"PeriodicalIF":2.9,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.17628","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142985882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring itch in hidradenitis suppurativa with lessons from atopic dermatitis and psoriasis","authors":"Nicole Trupiano,&nbsp;Kelly Young,&nbsp;Harika Echuri,&nbsp;Jalal Maghfour,&nbsp;Lauren A. V. Orenstein,&nbsp;Iltefat Hamzavi","doi":"10.1111/1346-8138.17622","DOIUrl":"10.1111/1346-8138.17622","url":null,"abstract":"<p>Itch is a prominent symptom in many cutaneous disorders, including atopic dermatitis (AD), prurigo nodularis, and psoriasis. Itch is also a common but overlooked concern in patients with hidradenitis suppurativa (HS). Currently, the mechanisms underlying itch in HS remain unclear. To gain a better understanding, we reviewed the literature on pruritus in HS and other itch-predominant disorders, AD, and psoriasis. In HS, psoriasis, and AD, we found that itch often co-localized with pain and occurred more frequently at night. Furthermore, itch was found to negatively affect sleep and increase the risk for comorbid psychiatric disorders in HS, psoriasis, and AD. However, HS-, psoriasis-, and AD-related itch differ in temporality. Itch in AD is often described as chronic, while itch in HS and psoriasis is often described as episodic. HS-associated itch is likely multifactorial, and several mechanisms have been proposed including peripheral sensitization, central sensitization, and neuroinflammation. Prior studies in HS highlight enhanced IgE production and a dense infiltration of mast cells, along with a variety of cytokines and chemokines. Furthermore, alterations in the skin microbiome may contribute to itch in HS. To date, few therapies have been studied to treat itch in HS. Given the efficacy of several biologics and small molecules in treating itch in AD and psoriasis, similar agents may be explored in future HS studies. Alternative therapies to target neurological and psychiatric contributions to itch may include anticonvulsants, cannabinoids, and nonpharmacological treatments. In conclusion, pathomechanisms of itch in HS remain to be fully elucidated. However, we can draw on lessons from other pruritic disorders to begin addressing the symptom of it and identify important questions for future study.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 2","pages":"239-246"},"PeriodicalIF":2.9,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142985881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment of facial reactive B-cell rich lymphoid proliferation with dapsone","authors":"Makoto Sugaya,&nbsp;Akari Nagashima,&nbsp;Risae Nakamura,&nbsp;Megumi Yano,&nbsp;Takashi Morita,&nbsp;Yasuko Niijima,&nbsp;Tomonori Takekoshi,&nbsp;Naoko Kanda,&nbsp;Masaru Tanaka","doi":"10.1111/1346-8138.17614","DOIUrl":"10.1111/1346-8138.17614","url":null,"abstract":"<p>Reactive B-cell rich lymphoid proliferation (rB-LP), once called pseudolymphoma, is a benign lymphoproliferative disorder, which is histologically characterized by dense dermal infiltrate forming reactive germinal centers with tingible body macrophages. The disease frequently involves the face, scalp, and ear lobes. Treatment includes topical or intralesional steroids, surgical resection, ultraviolet therapy, laser treatment, and radiation therapy. Cases with multiple skin lesions, however, are difficult to treat with local therapies. Oral steroids are sometimes used, although the variety of side effects and recurrence during decreases in the dosage are the main problem. Here we report seven cases of rB-LP treated with dapsone, which has anti-inflammatory effect. Although the number of cases was limited, there was a trend that patients with multiple nodules on both sides of the face showed a good response. The limitations of this study include it being a case series from a single institute, and possible effects of topical steroids. We can, however, safely say that dapsone may be useful in some patients with rB-LP.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 4","pages":"735-739"},"PeriodicalIF":2.9,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142974236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dermoscopic findings in two cases of trichogerminoma","authors":"George Miura,&nbsp;Takuya Maeda,&nbsp;Hideyuki Ujiie","doi":"10.1111/1346-8138.17610","DOIUrl":"10.1111/1346-8138.17610","url":null,"abstract":"<p>Trichogerminoma (TG) is a rare, benign, cutaneous adnexal tumor originating from the hair germ epithelium. It typically presents as an asymptomatic, slowly enlarging nodule predominantly on the head, face, or trunk. Despite its benign nature, precise diagnosis is crucial because of its potential to become malignant. There has been no previous report on the dermoscopic findings of TG. In this study, we reviewed the dermoscopic findings of two cases in detail and contrasted them with the pathological findings. In the first case, an 80-year-old male presented with a forehead nodule that was initially suspected to be basal cell carcinoma (BCC). Dermoscopic examination revealed arborizing vessels, milia-like cysts, and comedo-like openings. Histological examination supported a diagnosis of TG, showing basaloid cell nests with peripheral palisading and pathognomonic “cell balls.” The second case involved a 50-year-old female with a nodular lesion on her scalp. Dermoscopy showed arborizing vessels, milia-like cysts, and blue-gray ovoid nests. Based on the presence of “cell balls” observed in histopathological examination, this case was also diagnosed as TG. This report is seminal in documenting the specific dermoscopic patterns associated with TG, notably the presence of arborizing vessels in conjunction with features indicative of adnexal differentiation, such as milia-like cysts and comedo-like openings. Although differentiating TG from other follicular tumors such as BCC and trichoblastoma based solely on dermoscopy is challenging, these features suggest follicular differentiation in TG. This report contributes uniquely to the existing data on TG, enhancing our understanding of this rare tumor and how to diagnose it.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 4","pages":"730-734"},"PeriodicalIF":2.9,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142960811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of statins, gliptins, and antipsychotics with bullous pemphigoid: A case–control study in the Cretan population","authors":"Eirini Kavvalou,&nbsp;Konstantinos Krasagakis,&nbsp;Gregory Chlouverakis,&nbsp;Paraskevi Xekouki,&nbsp;Vasiliki Daraki,&nbsp;Charikleia Kouvidou,&nbsp;Eleni Lagoudaki,&nbsp;Sabine-Elke Krüger-Krasagakis","doi":"10.1111/1346-8138.17603","DOIUrl":"10.1111/1346-8138.17603","url":null,"abstract":"<p>Bullous pemphigoid (BP) is an autoimmune blistering disorder predominantly affecting the elderly. Recently, many studies have shed light on the effect of specific drug intake and comorbidities on the development of BP. The purpose of this study was to investigate the association of specific drug class intake and comorbidities with the development of BP in the Cretan population. Significant associations with BP were found for statins (odds ratio [OR] = 4.06, 95% confidence interval [CI] 1.99–8.27, <i>P</i> &lt; 0.001), gliptins (OR = 4.27, 95% CI 2.33–7.83, <i>P</i> &lt; 0.001), and antipsychotics (OR = 3.33, 95% CI 1.36–8.11, <i>P</i> = 0.006). Higher proportions of use in the BP group vs. control group were found for atorvastatin (OR = 1.86, 95% CI 1.04–3.32, <i>P</i> = 0.035), linagliptin (OR = 6.63, 95% CI 2.17–20.23, <i>P</i> &lt; 0.001), vildagliptin (OR = 3.20, 95% CI 1.73–5.91, <i>P</i> &lt; 0.001), alogliptin (OR = 5.11, 95% CI 1.19–22.04, <i>P</i> = 0.016), and quetiapine (OR = 4.21, 95% CI 1.5–11.85, <i>P</i> = 0.004). The presence of diabetes mellitus in the absence of gliptins did not show any significant effect on BP (OR = 1.60, 95% CI 0.79–3.23, <i>P</i> = 0.188). Metformin intake showed no significant association with BP (OR = 0.48, 95% CI 0.18–1.28, <i>P</i> = 0.143). Our findings confirm and extend previous studies reporting the association of gliptins and antipsychotics on BP in other European populations. The association found for statins is new, thus more studies are needed to corroborate its validity.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 2","pages":"291-298"},"PeriodicalIF":2.9,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.17603","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142960804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dangling digits","authors":"Lu Cao,&nbsp;Daiyue Wang,&nbsp;Ziqian Xu,&nbsp;Songting Wang","doi":"10.1111/1346-8138.17595","DOIUrl":"10.1111/1346-8138.17595","url":null,"abstract":"","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 2","pages":"e145-e146"},"PeriodicalIF":2.9,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142960809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment of refractory, inflammatory epidermolysis bullosa acquisita with a combination of dupilumab and systemic glucocorticoid","authors":"Xiaoxue Xing,&nbsp;Ye Liu,&nbsp;Li Chen,&nbsp;Yanjun Dan,&nbsp;Jie Ren","doi":"10.1111/1346-8138.17582","DOIUrl":"https://doi.org/10.1111/1346-8138.17582","url":null,"abstract":"","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 4","pages":"e308-e310"},"PeriodicalIF":2.9,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143793439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world assessment of the patient profile, clinical characteristics, treatment patterns, and outcomes associated with erythropoietic and X-linked protoporphyria","authors":"Samuel M. Silver,&nbsp;Katherine Houghton,&nbsp;Abby Hitchens,&nbsp;Valérie Derrien Ansquer,&nbsp;Malgorzata Ciepielewska","doi":"10.1111/1346-8138.17607","DOIUrl":"10.1111/1346-8138.17607","url":null,"abstract":"<p>Erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) are rare genetic disorders. There are limited data regarding how these disorders are managed in real-world settings. The aim of this study was to document the characteristics and treatment patterns among patients diagnosed with EPP or XLP in general real-world settings in the United States. We, therefore, conducted a retrospective medical record review of patients diagnosed with EPP or XLP on or before July 1, 2020. Data were analyzed for patients with EPP (<i>n</i> = 299) and XLP (<i>n</i> = 91). Outcomes included demographic and clinical characteristics, diagnostic testing, therapy recommendations, office visits, emergency department visits, and hospitalizations. Costs were assigned to healthcare resources. Mean (standard deviation [SD]; median) time between the first symptom documented in the medical records and diagnosis was 2.9 (5.1; 1.3) years. The most common pre-diagnostic tests were liver function, total plasma and erythrocyte protoporphyrin, genetic tests, and renal function. Patients were advised to use sunscreen (85%) or modify their lifestyle (83%). Within 12 months of diagnosis, the mean (SD; median) number of office visits, emergency department visits, and inpatient hospitalizations related to EPP or XLP were 4.0 (3.5; 3.0), 0.8 (1.6; 0), and 0.4 (1.3; 0), respectively. Patients with EPP or XLP have several unmet needs, including timely and accurate diagnosis, symptom relief, and efficacious prevention of phototoxic reactions.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 3","pages":"416-422"},"PeriodicalIF":2.9,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.17607","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142934157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}